Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IPH5201 + durvalumab + oleclumab
- Development stage
- Unknown
- Lead developer
- Innate Pharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
A three-drug combination of monoclonal antibodies: IPH5201 (an anti-CD39 blocking antibody), durvalumab (an anti-PD-L1 antibody, brand name Imfinzi), and oleclumab (an anti-CD73 antibody, code name MEDI9447). This combination is being investigated for cancer immunotherapy, particularly in non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC). Each target (CD39, PD-L1, CD73) is implicated in immunosuppression within the tumor microenvironment. Inhibition of these targets aims to promote anti-tumor immunity by preventing adenosine production (via CD39 and CD73) and releasing the PD-L1/PD-1 checkpoint brake on T cells (via PD-L1)[1][4][6].
- Other names
- anti-CD39 antibody + anti-PD-L1 antibody + anti-CD73 antibody
02
Targets
ENTPD1 (Ectonucleoside triphosphate diphosphohydrolase 1)CD274 (Programmed cell death protein 1 ligand 1)NT5E (Cluster of Differentiation 73)
Beyond the preview
Go deeper on IPH5201 + durvalumab + oleclumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IPH5201 + durvalumab + oleclumab.